L'Oréal-owned Galderma Pharma S.A. and Swiss company Spirig Pharma A.G., which focuses on the development, production and marketing of dermatological products, announced they have entered into a definitive agreement under which Galderma will acquire Spirig.
"We are delighted to join forces with Spirig Pharma," said Humberto C. Antunes, CEO of Galderma: "Spirig has a holistic approach to protecting, treating, restoring and preventing dermatological conditions, which is closely aligned to that of Galderma. With this acquisition, Galderma will become the dermatology market leader in Switzerland, our home country. Additionally, with our global presence, we will be able to make Spirig's outstanding products available to a larger number of patients around the world."
Beat Sägesser, CEO of Spirig, commented, "Becoming part of Galderma will provide Spirig with the ideal conditions in which to develop and take its business to a new level and provide new opportunities for our employees."
Spirig's products include brands such as Excipial, Daylon and Daylong Actinica. Based in Egerkingen, Spirig has 390 employees in total and generated sales of CHF 98.4 million in 2011. Galderma intends to utilize Spirig's Egerkingen location as headquarters to its Swiss market operations and as a center of excellence. The global corporate headquarters of Galderma remain in Lausanne.
"We are excited about our two companies' commercial and geographic opportunities, maximizing the value of our complementary product portfolios in the prescription and self-medication markets," said Albert Draaijer, Galderma's vice president, business development and markets, who also leads Galderma's self-medication and aesthetic and corrective businesses. "We look forward to welcoming Spirig employees and to combining our efforts to better meet the market's needs."